Amgen Inc. is a biotechnology company dedicated to discovering, developing, manufacturing, and delivering human therapeutics. It focuses on addressing high unmet medical needs to enhance health outcomes and improve lives. Operating primarily in the human therapeutics segment, Amgen's extensive portfolio includes well-known products such as Aranesp, ENBREL, Prolia, Neulasta, Otezla, and Repatha, among others. These therapies target various conditions, showcasing Amgen's commitment to leveraging its expertise in biotechnology to provide innovative solutions for patients.
When researching a stock like Amgen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from AMGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for AMGN stock — the real life supply and demand for the stock over time — and examines that data in different ways. |
59.78
Free AMGN Email Alerts:
Video: Technical Analysis